CYLD is a deubiquitination enzyme that regulates different cellular processes, such as cell proliferation and cell survival. Mutation and loss of heterozygosity of the CYLD gene causes development of cylindromatosis, a benign tumour originating from the skin. Our study shows that CYLD expression is dramatically downregulated in basal cell carcinoma (BCC), the most common cancer in humans. Reduced CYLD expression in basal cell carcinoma was mediated by GLI1-dependent activation of the transcriptional repressor Snail. Inhibition of GLI1 restored the CYLD expression-mediated Snail signaling pathway, and caused a significant delay in the G1 to S phase transition, as well as proliferation. Our data suggest that GLI1-mediated suppression of CYLD has a significant role in basal cell carcinoma progression.
Introduction
CYLD is a deubiquitination enzyme responsible for removal of lysine 63 (K63) linked polyubiquitin chains from different substrates. It can interfere with signaling pathways such as NF-kB, JNK and p38 MAPK (reviewed in Massoumi (2010) ). The CYLD gene product is ubiquitously expressed in humans and mice in skin and hair follicles (Massoumi, 2010) . CYLD was recently observed to become elevated in the catagen phase of the hair cycle, when cell proliferation ceases (Moriwaki et al., 2007) . Originally it was discovered that mutations in the CYLD gene cause development of cylindroma (Bignell et al., 2000) . Further, reduced or even loss of CYLD protein expression in the tumor islands isolated from cylindroma patients was detected together with the expression of hair-specific keratins (Massoumi et al., 2006b) . Besides cylindroma, CYLD expression was also reduced in melanoma mediated by the occupancy of the CYLD promoter by Snail1 (Massoumi et al., 2009) . Removal of Snail1 from the promoter site restored CYLD expression and affected cyclin D1 expression, as well as the proliferation rate of melanoma (Massoumi et al., 2009 ). An increase in the cyclin D1 expression and proliferation rate of cells was also observed in the fast-growing papillomas isolated from CYLD-deficient mice (Massoumi et al., 2006a) .
Basal cell carcinoma (BCC) and squamous cell carcinoma are the most common types of human skin cancer. BCC mainly results from mutations that activate Hedgehog (Hh) signaling, leading to activation and over-expression of the GLI family transcription factors GLI1 and GLI2 (reviewed in Epstein (2008) ). Overexpression of either transcription factor in the epidermis and hair follicles of transgenic mice is sufficient to induce skin BCC-like tumors (Grachtchouk et al., 2000; Nilsson et al., 2000) . By regulating genes implicated in tumor progression, GLI factors transform normal epithelial cells into tumor cells in a relatively direct fashion (reviewed in Altaba et al. (2002) ; Kasper et al. (2006) ), without the need for other multiple genetic changes. For instance, several studies identified Snail1 as an early and direct transcriptional response gene of GLI1 (Louro et al., 2002; Karhadkar et al., 2004; Li et al., 2006 Li et al., , 2007 Fiaschi et al., 2009) . The induction of Snail expression and epithelial-mesenchymal transition by GLI1 was offered as an explanation for certain histopathological features of BCC, such as the absence of a well-defined intraepithelial precursor lesion (Li et al., 2006) .
We found reduced expression of CYLD in BCC. This effect was mediated by sustained GLI1 or Gli2 activity, and elevated levels of Snail1. Downregulation of GLI1 and Snail1 could restore the expression of CYLD and control of proliferation rate in keratinocytes.
Results and discussion
To explore the function of CYLD in non-melanoma skin cancer, we evaluated CYLD expression in human BCC. We found strong reduction or absence of CYLD expression at the site of tumors, whereas keratinocytes in the normal epidermis displayed high CYLD expression in the cytoplasm (Figure 1a ). To find whether CYLD expression is regulated during different stages of BCC, we characterized CYLD reactivity by immunohistochemistry in 12 paraffin-embedded BCC samples with different degrees of invasive behavior and tumour size, including superficial, nodular, sclerosing and infiltrating types (Supplementary Table S1 ). We could observe downregulation or even loss of CYLD in 11 out of 12 patients (Supplementary Table  S1 ). Interestingly, reduced CYLD expression in the early phase of BCC might suggest that CYLD repression occurs in an early stage of BCC development.
We have shown in previous studies that CYLD reduces proliferation and cyclin D1 expression by slowing the G1/S phase transition in keratinocytes and melanoma cells (Wickstrom et al., 2010) . To investigate whether the cells with reduced CYLD expression were proliferating, we used the proliferation marker Ki-67 and cyclin D1. The results showed that epithelial cells from the superficial BCCs were more proliferative and did not express CYLD (Figure 1b , Supplementary Figure S1 and Supplementary Table S2 ). In agreement with the previous studies (Yang et al., 2008) , immunostaining for Ki67 and cyclin D1 revealed that proliferating cells were increased at the periphery and outermost layers (Figure 1b and Supplementary Figure S1 ). Sustained Wnt-mediated b-catenin nuclear accumulation and increased expression of cyclin D1, can explain the proliferation status of tumor cells at the periphery (Yang et al., 2008) .
Snail has been identified as an early GLI1-responsive gene in the skin and was shown to be co-expressed with GLI1 in skin tumors (Li et al., 2006) . We confirmed combined upregulation of GLI1 and Snail1 in BCC (Supplementary Figure S2) . Comparing Snail1, CYLD and GLI1 expression in the sequential immunostaining, we found reduced CYLD expression and elevated levels of Snail1 and GLI1 (Figure 1c and Supplementary  Table S2 ). In agreement with this result, we observed loss of CYLD expression and elevated levels of GLI1 and Snail1 expression in freshly isolated BCC samples, both at the protein ( Figure 1d ) and mRNA level (Supplementary Figure S3 ) compared with the adjacent normal skin.
To analyse whether modification of the Hh/GLI pathway can regulate CYLD expression, we used human keratinocyte cells (HaCaT) expressing GLI1 GLI1 regulates CYLD in BCC S Kuphal et al under tetracycline control (Regl et al., 2002) and found induction of GLI1 already 6 h after tetracycline treatment ( Figure 2a ). The kinetics of Snail1 accumulation closely paralleled that of GLI1 protein ( Figure 2a ). In contrast to this induction, CYLD expression was repressed when the cells were treated with tetracycline ( Figure 2a ). The results obtained from western blotting were further confirmed by using immunohistochemistry analysis (Supplementary Figure S4a) . As expected, purmorphamine treatment, which was previously found to activate the Hh pathway, elevated the levels of GLI1 and Snail1, and reduced the level of CYLD both at the mRNA ( Figure Figure S5 ) using short-hairpin RNA reduced Snail and increased CYLD expression at the mRNA levels in BCC cell lines (CSZ-1 and ASZ001 (So et al., 2006) ). In contrast to this, over-expression of GLI1 or GLI2 in normal human epidermal keratinocytes or HaCaT cells reduced CYLD and increased Snail1 expression at the mRNA level ( Figure 2d and Supplementary Figure S6 ). These results suggest that CYLD and Snail1 are two early genes that are regulated by GLI1 and GLI2, and that Hh-mediated GLI activation and expression is responsible for downregulation of CYLD. We have previously shown that CYLD prevents nuclear accumulation of Bcl-3 through a deubiquitination mechanism leading to reduced proliferation rates of keratinocytes (Massoumi et al., 2006a) . In the current experiment we found epithelial cells from the superficial BCCs to contain Bcl-3 localized in the nucleus (Figure 3a) . These results were confirmed by analysing BCC tissue samples from mice expressing constitutively active Smo in the epidermis in response to tamoxifen administration (K5creERT;R26SmoM2; Jeong et al., 2004; Nitzki et al., 2010) . As shown in Figure 3b , we detected strong expression of nuclear Bcl-3 protein in both early (45 days post-tamoxifen injection) and full-blown BCC-like lesions (90 days post-tamoxifen injection). By contrast, normal skin samples were generally low in Bcl-3 expression. Treatment of primary mouse keratinocytes with purmorphamine or untreated GLI1 regulates CYLD in BCC S Kuphal et al ASZ001 cells showed ubiquitination ( Figure 3c ) and nuclear localization of Bcl-3 (Figure 3d ). We could not detect any ubiquitination of Bcl-3 or nuclear localized Bcl-3 in non-treated HaCaT or mouse primary keratinocytes (Figures 3c and d) . Furthermore, Bcl-3 was shown to be localized in the nucleus of ASZ001 cells, whereas cyclopamine treatment of these cells reduced nuclear localization of Bcl-3 (Figure 3d ). These results suggest that reduced or loss of CYLD expression observed in BCC promotes nuclear localization of Bcl-3.
To determine whether downregulation of CYLD by GLI1 in keratinocytes is mediated by Snail1, we first tried to establish whether Snail1 can be recruited to the promoter of CYLD upon GLI1 induction. Chromatin GLI1 regulates CYLD in BCC S Kuphal et al treated keratinocytes. We then observed upregulation of CYLD (Figure 4b , left panels) and deubiquitination of Bcl-3 (Figure 4b , right panels), using two different Snail1 siRNA oligos. To further investigate the consequences of the reduced levels of CYLD mediated by GLI1-Snail1 signaling, both proliferation and cell cycle assays were applied. Consistent with previous data (Regl et al., 2002) , tetracycline-induced upregulation of GLI1 (Supplementary Figure S7) increased the proliferation rate of keratinocytes (Figure 4c ). Transient transfection of keratinocytes with full-length HA-tagged CYLD expression vector (Supplementary Figure S7) or treatment of cells with Snail1 siRNA (Supplementary Figure S7 ) reduced cell proliferation rate significantly (Figure 4c ). We could not observe any difference in cell viability comparing control cells with cells transfected with either CYLD or Snail-siRNA (data not shown).
Our results, therefore, suggest that GLI1-mediated downregulation of CYLD through Snail1 promotes proliferation. Hh/GLI signaling has been shown to induce proliferation via activation of critical G1/S cell cycle genes, including D-type cyclins (Kenney and Rowitch, 2000; Regl et al., 2004) . We recently demonstrated that CYLD reduces cell proliferation by decreasing the rate of cell division at the G1/S phase (Wickstrom et al., 2010) . Here, we found that release of synchronized keratinocytes by addition of tetracycline caused a delay in G1 to S phase transition in CYLD-transfected cells, but not in mock-transfected cells (Figure 4d ). Keratinocytes in the presence of siRNA-mediated depletion of Snail1 revealed a significant delay in G1/S phase, compared with siRNA-control cells (Figure 4d ). These results were confirmed by using a second Snail1 siRNA oligonucleotide, or transfection of cells with an untagged CYLD (Supplementary Figures S8, S9 and S10). Our observations collectively suggest that reduced expression of CYLD in response to sustained upregulation of GLI1 and Snail1 in BCC induces an increase in cell proliferation by promoting G1 to S phase progression.
Our study uncovers a new mechanism in the GLI1-mediated Hh signaling pathway responsible for progression of BCC. This mechanism is based on the suppression of CYLD gene product by the transcriptional regulator Snail, whose expression is activated by GLI1 and likely by GLI2, thereby promoting the aggressive phenotype of keratinocytes or BCC. One might hypothesize that a similar signaling pathway mediated by CYLD and GLI1, which we could observe in human BCCs, is also operating during hair follicle development. This hypothesis is based on the previous studies demonstrating that Snail and GLI1 transcripts are elevated in normal anagen (growth) phase hair follicles, in contrast to CYLD, whose expression is elevated only during the catagen (regression) phase of the hair cycle (Moriwaki et al., 2007) . Our findings indicate that following progression, constitutively high GLI1 and Snail1 expression allows BCC to repress CYLD at transcriptional levels, while increasing the proliferation rate through cyclin D1 expression and Bcl-3 nuclear localization. Indeed, immunohistochemistry analysis of three invasive BCCs expressing the suggested pathway molecules highlighted the significance of the present finding (Supplementary Table S2 ). Administration of SMO inhibitor (GDC-0449) as a part of phase I study in metastatic or locally advanced BCC in 33 patients resulted in 18 objective response. Among these patients, 2 had a complete and 16 had a partial response (Von Hoff et al., 2009 ) and other new SMO inhibitors are currently under clinical investigation. Our data suggest that targeting the Hh downstream components identified in the present study is of therapeutic relevance. In addition to the regulation of EMT, the Snail family members function as regulators of proliferation or apoptosis. In this regard, suppression of Snail1, which functions as regulator of proliferation/apoptosis in different tumor types, alone or in combination with GLI may be considered as a potential anticancer approach in BCC, particularly in case of resistance to SMO inhibitors Buonamici et al., 2010) or in patients with recurrence as second line therapy. Future investigation may also clarify the function of Bcl-3 in BCC and normal skin, and address whether a combination of CYLD, Bcl-3 and Snail can be used as a detection marker for specific stages of BCC. Such assessments would have major clinical implications for the appropriate selection of treatment.
Materials and methods
Cell culture, transfection and flow cytometry The T-REx system (Invitrogen, Carlsbad, CA, USA) to generate stable HaCaT lines expressing GLI1 or GLI2 under the control of the tetracycline repressor has been described previously (Regl et al., 2002) . Transient transfection assay using CYLD expression plasmid or Snail1 siRNA were made with Lipofectamine transfection reagent (Qiagen, Sollentuna, Sweden) and were performed as described previously (Massoumi et al., 2009) . SiRNA were purchased from TAG Copenhagen A/S (Copenhagen, Denmark, Supplementary Table S3) .
Nucleofection of normal human epidermal keratinocytes was performed using the Human Keratinocyte Nucleofector Kit from Lonza (Basel, Switzerland). Manufacturer's instructions have been slightly modified. A total of 5 Â 10 5 cells were resuspended in 100 ml complete nucleofector solution. The GLI1/GLI2-pcDNA4/TO plasmid was then added (2 mg/ transfection sample) to the cell suspension. As a control, cells received the empty expression construct. The cell/DNA mixtures were transferred into certified cuvettes (Lonza) and transfected by using amaxa biosystems instrument (Amaxa Biosystems, Basel, Switzerland). Following the electroporation, the cells were incubated in culture medium pre-heated to 37 1C for 1 day, and then seeded for mRNA isolation. Quantitative real-time PCR was performed with specific primers for CYLD, Cyclin D1, GLI1 and Snail1 (Supplementary Table S2 ). The cell cycle analysis of primary keratinocytes post synchronisation was performed as described previously (Wickstrom et al., 2010) . Lentiviral GLI1 or GLI2 short-hairpin RNA constructs were purchased from the Mission RNAi set (Sigma, St Louis, MO, USA) and murine BCC cells were stably transduced as described previously (Kasper et al., 2007) .
Proliferation assay
HaCaT cells were grown in 6-well plates in the absence or presence of tetracycline. After 24 h of incubation the cells were GLI1 regulates CYLD in BCC S Kuphal et al transfected with empty vector (control), full-length HA-tagged or -untagged CYLD expression vector, siRNA-control or siRNA-Snail1 and incubated for an additional 48 h. Each treatment was carried out in duplicate. Cell viability assays were counted in triplicate, using a Bu¨rker counting chamber using trypan blue (ICN Biomedicals Inc., Aurora, OH, USA).
Immunohistochemical analysis
Induction of BCC in animals was performed as described previously (Nitzki et al., 2010) . Briefly, SmoM2 expression was induced 28 days post birth by i.p. injection of 1 mg/day tamoxifen over a period of 5 days. Mice were killed 45 or 90 days after tamoxifen injection and tissues were embedded in paraffin. Human skin biopsies of BCC were collected in the Department of Dermatology and the Institute of Pathology, University Hospital Regensburg, Germany. As prescribed by the medical ethical committee of the University of Regensburg, Germany, data privacy was protected and safeguards were put in place to protect the identity of the subjects used in the study. The authors received approval of the ethics committee of the University of Regensburg to conduct the in vitro studies.
To test the specificity of antibodies, we have used nontreated or tetracycline-treated (48-h) HaCaT cells expressing GLI1 under tetracycline control. These cells were harvested by trypsinization, washed in phosphate buffered saline, fixed in 4% paraformaldehyde for 20 min, stained with Meyer's hematoxylin for 5 min and centrifuged at 1500 r.p.m. for 5 min with the subsequent pellet resuspended in ice-cold 70% ethanol. Pellet were dehydrated in graded ethanol series, embedded in paraffin and incubated with primary antibody (Supplementary  Table S2 ). After washing the sections were incubated with HRP-conjugated secondary antibody for 30 min (Envision System; DAKO, Glostrup, Denmark), before incubation with DAB þ Substrate-Chromogen solution for 10 min (DAKO) according to the manufacturers' instructions. Bcl-3 blocking peptide (#sc-185p; Santa Cruz Biotech, Santa Cruz, CA, USA) for competition study was used in 1:2 dilution (2 mg/ml).
Immunoprecipitation and chromatin immunoprecipitation
Immunoprecipitation of Bcl-3 was performed as described previously. Chromatin immunoprecipitation was performed according to the manufacturer's (IMGENEX Corporation, San Diego, CA, USA) instructions using polyclonal antibodies against Snail1 (clone E-18, Santa Cruz) and negative control rabbit immunoglobulin (DAKO) as control. The extracted DNA was used for semiquantitative PCR to amplify the CYLD promoter region using specific primes (Supplementary  Table S2 ).
Statistical analysis
Data are presented as mean ± s.e.m. Statistical comparisons were assessed with an analysis of variance or Student's t-test; Po0.05 was taken as significant.
